Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells

Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells

Abstract Background Gemcitabine is the standard first-line chemotherapy regimen for pancreatic cancer. However, its therapeutic value is substantially limited in pancreatic cancer patients due to occurrence of resistance towards gemcitabine. A strategy of combined chemo-regimens is widely employed i...

Full description

Bibliographic Details
Main Authors: Hehe Li, Zhengle Zhang, Chenggang Gao, Shihong Wu, Qingke Duan, Heshui Wu, Chunyou Wang, Qiang Shen, Tao Yin
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Cell & Bioscience
Subjects:
Pancreatic cancer
Gemcitabine
Valproic acid
Combined chemotherapy
Bmi1
Online Access:http://link.springer.com/article/10.1186/s13578-019-0312-0

Internet

http://link.springer.com/article/10.1186/s13578-019-0312-0

Similar Items